.svg)
OUR MUlti-target
Pipeline
We have accelerated our lead 1st-in-class compound from early discovery to Phase 2 in 2.5 years with seed capital. Using our “Platform-in-a-Mechanism” model, we have built a pipeline across 2 different targets for 3 therapeutic areas. We plan to accelerate 2 additional indications to IND in next 12 months using our super-efficiency model.
© Copyright 2018-2026. All rights reserved.
%2C%20Color%3DOriginal.svg)
